Use of non-subtype b gag proteins for lentiviral packaging
AssigneesTheravectys, Institut Pasteur
InventorsThi-Lan Tran, Pierre Charneau, Cecile Bauche
Life of this patent
Estimating the term…
Abstract
The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.
Claims19
A replication-defective lentiviral packaging vector lacking a ψ site and encoding an HIV-1 Gag MA protein;
- wherein the HIV-1 Gag MA protein:
- a) has an amino acid at position 12 that is not a glutamic acid,
- b) has an amino acid at position 15 that is not an arginine,
- c) does not have both a valine at position 46 and a leucine at position 61;
- and
- wherein the lentiviral packaging vector encoding the HIV-1 Gag MA protein generates at least a 1.5 fold increase in the titer of a packaged lentiviral vector as compared to the lentiviral packaging vector encoding an HIV-1 Gag MA protein of HIV-1 BRU.
A method for generating a packaging vector comprising inserting a Gag and/or Pol sequence from a non-subtype B HIV-1 virus into a plasmid under the control of a non-HIV promoter to generate the packaging vector.
A method for generating a lentiviral vector comprising administering a packaging vector encoding a non-subtype B HIV-1 Gag or Pol protein to a cell with a lentiviral vector.
Dependencies are inferred from the claim text.